count, GvHD prophylaxis with cyclosporine, and CBT during the earlier period (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) were associated with poorer survival (P o 0.1). Nucleated cell counts in the graft had no significant difference in OS in the whole cohort or in each group of conditioning. In the multivariate analysis including these factors, the HDCA/CY/TBI group showed a significantly lower overall mortality than the CY/TBI group (Supplementary Table 1 ; HR, 0.75; 95% CI, 0.57-0.99; P = 0.04). This superiority of OS in the HDCA/CY/TBI group was observed in each subgroup according to the patient characteristics, such as age, disease risk, phenotype, existence of abnormal chromosome, initial leukocyte counts and year of CBT. In addition, MRD (one of the most important prognostic factors 1, 2 ) was determined by flow cytometric analyses in 80% of the cohort, and HDCA/CY/TBI showed the superiority in OS irrespective of the existence of MRD (data not shown). A difference in OS was detected even with the other common cutoff point for age (⩾35 years) 5 (HR, 0.75; 95% CI, 0.57-1.00; P = 0.05).
Relapse, tumor-related mortality and NRM were also calculated. Relapse in patients transplanted in CR was significantly reduced in the HDCA/CY/TBI group (Figure 1b) . Tumor-related mortality including the entire cohort was also significantly lower in the HDCA/CY/TBI group (Figure 1c; Supplementary Table 2) . Leukemia-free survival also showed superiority in the HDCA/CY/ TBI regimen (HR, 0.77; 95% CI, 0.59-1.00; P = 0.05). Post-CBT central nervous system (CNS) relapse was less often observed in HDCA/CY/TBI (0.9%) than in CY/TBI (2.7%; P = 0.17) despite the higher incidence of CNS involvements before CBT in the HDCA/ CY/TBI group (6.2% vs 3.6%). HDCA/CY/TBI was not found to induce any significant increase of NRM in the entire cohort (Figure 1d ; Supplementary Table 2) or in any subgroup of patient age or disease risk (data not shown).
To address the clinical courses that led to the differences in survival and relapse, we focused on the engraftment, GvHD and several common complications after CBT in each group (Supplementary Table 3 ). The HDCA/CY/TBI group showed a higher proportion of neutrophil engraftment after CBT (Supplementary Table 3 ; Supplementary Figure 1A) . The median periods to reach neutrophil engraftment were not significantly different between the groups (23 days in HDCA/CY/TBI vs 22 days in CY/TBI; P = 0.11). Platelet recovery was observed in a significantly larger proportion of patients (Supplementary  Table 3 ; Supplementary Figure 1B ) and in earlier days after CBT in the HDCA/CY/TBI group (45 vs 52 days; P o 0.01). The incidence of acute GvHD showed an increase in HDCA/CY/TBI; however, there was no significant difference incidence between the groups (Supplementary Table 3 ; Supplementary Figure 1C) , whereas the incidence of chronic GvHD (cGvHD) was significantly higher in the HDCA/CY/TBI group (HR, 1.86; P o 0.01; Supplementary Table 3; Supplementary Figure 1D ). Concerning other post-CBT complications, the addition of HDCA did not increase any types of infectious episodes (Supplementary Table  3 ), whereas CNS toxicity and thrombotic microangiopathy (TMA)
were documented more frequently in HDCA/CY/TBI (Supplementary Table 3) .
We compared the causes of NRM between CY/TBI and HDCA/CY/TBI to investigate the consequences of these differences on the clinical courses (Supplementary Table 4 ). The major causes of NRM were infection and organ failure in both groups, and there were no significant differences in the incidence of death causes between the two regimens, including TMA and GvHD. No cases of fatal CNS toxicity were documented in our cohort. These indicate that cGvHD and other HDCA-related complications could be controlled, and that they did not induce additional fatal complications in the HDCA/CY/ TBI group.
The present cohort study on the HDCA/CY/TBI regimen in CBT for ALL revealed two major findings: (1) the HDCA/CY/TBI regimen improved OS through reduction in relapse and tumor-related mortality; and (2) addition of HDCA increased the incidence of cGvHD, CNS toxicity and TMA after CBT, but was not related to a higher NRM.
First, we clearly showed the superiority of HDCA/CY/TBI over CY/TBI concerning OS. This result may be due, in part, to the strong anti-leukemia effects of HDCA. Compared with normal dose of cytarabine, HDCA can exert stronger effects because of its longer time in contact with leukemia cells 11 and its broader distribution in the whole body, including the cerebrospinal fluid; 12 these pharmacokinetic and pharmacodynamic features of HDCA can support our findings of reduced relapse and improved prognosis.
Furthermore, a stronger GvL effect in the HDCA/CY/TBI regimen, indicated by the higher incidence of cGvHD in this group, may also be involved in reducing the incidence of relapse; the occurrence of cGvHD is known to be closely correlated with the existence of strong GvL effects. 13 The intensity of conditioning regimens is reportedly related to GvHD incidence, 14 and a higher incidence of GvHD in HDCA/CY/TBI was indeed observed in a previous study of AML. 10 These dual effects of HDCA, that is, anti-leukemia effect and enhanced stronger GvL effect, may work synergistically to reduce tumorrelated mortality and account for the superiority of HDCA/CY/TBI after CBT.
Second, we showed that HDCA/CY/TBI is related to a higher incidence of CNS toxicity and TMA among various common posttransplant complications, in addition to cGvHD. The prognosis is seldom severe after a CNS complication; however, sufficient attention should be paid as a common adverse event after the HDCA/CY/TBI regimen. On the other hand, TMA, which is caused by vascular endothelial cell injury, is not specific to HDCA, but related to a higher intensity of conditioning regimens and to posttransplant GvHD in general. 9, 15 TMA can sometimes be a fatal complication, and prophylaxis for TMA such as recombinant thrombomodulin 15 may be considered in HDCA/CY/TBI. Despite the higher incidence of these complications, the total NRM and its causes showed no differences between HDCA/CY/TBI and CY/TBI, which supports the feasibility of this HDCA/CY/TBI regimen in myeloablative CBT for ALL.
This study has some limitations due to its retrospective cohort nature, such as selection bias in the choice of conditioning regimens, although the patient characteristics in Table 1 showed no significant differences between the two groups. Information on the CBT centers where each patient received transplantation was not available from this database. To overcome these limitations, randomized controlled studies comparing HDCA/ CY/TBI and CY/TBI should be planned. These studies will be helpful in establishing new myeloablative conditioning regimens, including HDCA administration, and in improving the total prognosis of ALL. Abbreviations: CBT = cord blood transplantation; CY = cyclophosphamide; CyA = cyclosporine; F to M = female to male; HDCA = high-dose cytarabine; M to F= male to female; MMF = mycophenolate mofetil; MTX = methotrexate; NCC = nucleated cell count; nCR = not CR; Ph = Philadelphia; PIF = primary induction failure; PtBW = body weight of patients; Tac = tacrolimus. 
